RESUMEN
Biomarker profiles of acute rejection in liver transplant recipients could enhance the diagnosis and management of recipients. Our aim was to identify diagnostic proteoform signatures of acute rejection in circulating immune cells, using an emergent "top-down" proteomics methodology. We prepared differentially processed and cryopreserved cell lysates from 26 nonviral liver transplant recipients by molecular weight-based fractionation and analyzed them by mass spectrometry of whole proteins in three steps: (i) Nanocapillary liquid chromatography coupled with high-resolution tandem mass spectrometry; (ii) database searching to identify and characterize intact proteoforms; (iii) data processing through a hierarchical linear model matching the study design to quantify proteoform fold changes in patients with rejection versus normal liver function versus acute dysfunction without rejection. Differentially expressed proteoforms were seen in patients with rejection versus normal and nonspecific controls, most evidently in the cell preparations stored in traditional serum-rich media. Mapping analysis of these proteins back to genes through gene ontology and pathway analysis tools revealed multiple signaling pathways, including inflammation mediated by cytokines and chemokines. Larger studies are needed to validate these novel rejection signatures and test their predictive value for use in clinical management.
Asunto(s)
Biomarcadores/sangre , Rechazo de Injerto/diagnóstico , Leucocitos Mononucleares/metabolismo , Trasplante de Hígado/efectos adversos , Proteoma/análisis , Bases de Datos de Proteínas , Femenino , Rechazo de Injerto/sangre , Rechazo de Injerto/etiología , Humanos , Masculino , Persona de Mediana Edad , Pronóstico , Isoformas de Proteínas , ProteómicaAsunto(s)
Anticuerpos Monoclonales/uso terapéutico , Inmunoglobulina G/uso terapéutico , Inmunosupresores/uso terapéutico , Intestinos/trasplante , Trasplante Homólogo/inmunología , Adulto , Anticuerpos Monoclonales Humanizados , Niño , Daclizumab , Femenino , Rechazo de Injerto/patología , Humanos , Intestinos/patología , Masculino , Trasplante Homólogo/patologíaAsunto(s)
Rechazo de Injerto/inmunología , Supervivencia de Injerto , Prueba de Histocompatibilidad , Intestinos/trasplante , Linfocitos T Citotóxicos/inmunología , Trasplante Homólogo/inmunología , Adulto , Anticuerpos Monoclonales/uso terapéutico , Anticuerpos Monoclonales Humanizados , Niño , Daclizumab , Femenino , Estudios de Seguimiento , Rechazo de Injerto/prevención & control , Humanos , Inmunoglobulina G/uso terapéutico , Inmunosupresores/uso terapéutico , Masculino , Muromonab-CD3/uso terapéutico , Complicaciones Posoperatorias/clasificación , Complicaciones Posoperatorias/epidemiología , Estudios Retrospectivos , Tasa de Supervivencia , Factores de Tiempo , Trasplante Homólogo/mortalidad , Trasplante Homólogo/fisiologíaAsunto(s)
Intestinos/trasplante , Ácido Micofenólico/análogos & derivados , Complicaciones Posoperatorias/clasificación , Trasplante Homólogo/métodos , Vísceras/trasplante , Adulto , Azatioprina/uso terapéutico , Niño , Estudios de Seguimiento , Rechazo de Injerto/tratamiento farmacológico , Rechazo de Injerto/epidemiología , Humanos , Inmunosupresores/uso terapéutico , Incidencia , Muromonab-CD3/uso terapéutico , Ácido Micofenólico/uso terapéutico , Infecciones Oportunistas/epidemiología , Complicaciones Posoperatorias/epidemiología , Estudios Retrospectivos , Factores de Tiempo , Trasplante Homólogo/inmunología , Insuficiencia del TratamientoRESUMEN
BACKGROUND: Tacrolimus (Tac) and mycophenolate mofetil (MMF) are newly approved immunosuppressive agents. However, the safety and efficacy of the combination of MMF and Tac in primary liver transplantation has not been determined. METHODS: An Institutional Review Board-approved, open-label prospective randomized protocol was initiated to study the efficacy and toxicity of Tac and steroids (double-drug therapy) versus Tac, steroids, and MMF (triple-drug therapy) in primary adult liver transplant recipients. Both groups of patients began on the same doses of Tac and steroids. Patients randomized to triple-drug therapy also received 1 g of MMF twice a day. RESULTS: Between August 1995 and January 1997, 200 patients were enrolled, 99 in double-drug therapy and 101 in triple-drug therapy. All patients were followed until May 1997, with a mean follow-up of 12.7 months. During the study period, 28 of 99 patients in double-drug therapy received MMF to control ongoing acute rejection, nephrotoxicity, and/or neurotoxicity. On the other hand, 61 patients in triple-drug therapy discontinued MMF for infection, myelosuppression, and/or gastrointestinal disturbances. By an "intention-to-treat analysis," the actuarial 1-year patient survival rate was 85.1% in double-drug therapy and 83.1% in triple-drug therapy (P=0.77). The actuarial 1-year graft survival rate was 80.2% for double-drug therapy and 79.2% for triple-drug therapy (P=0.77). Forty-one patients (41.4%) in double-drug therapy and 32 (31.7%) in triple-drug therapy had at least one episode of rejection, but this was not statistically significant (P=0.15). The mean maintenance dose of corticosteroids was slightly lower in triple-drug compared with double-drug therapy. CONCLUSION: Patient and graft survival rates were similar in both groups. There was a trend to a lower incidence of rejection, reduced nephrotoxicity, and a lesser amount of maintenance corticosteroids in triple-drug therapy compared with double-drug therapy.
Asunto(s)
Inmunosupresores/uso terapéutico , Trasplante de Hígado/inmunología , Ácido Micofenólico/análogos & derivados , Tacrolimus/uso terapéutico , Adulto , Método Doble Ciego , Quimioterapia Combinada , Femenino , Rechazo de Injerto/prevención & control , Supervivencia de Injerto , Humanos , Masculino , Ácido Micofenólico/uso terapéutico , Estudios Prospectivos , Tasa de SupervivenciaRESUMEN
BACKGROUND: Although tacrolimus-based immunosuppression has made intestinal transplantation feasible, the risk of the requisite chronic high-dose treatment has inhibited the widespread use of these procedures. We have examined our 1990-1997 experience to determine whether immunomodulatory strategies to improve outlook could be added to drug treatment. STUDY DESIGN: Ninety-eight consecutive patients (59 children, 39 adults) with a panoply of indications received 104 allografts under tacrolimus-based immunosuppression: intestine only (n = 37); liver and intestine (n = 50); or multivisceral (n = 17). Of the last 42 patients, 20 received unmodified adjunct donor bone marrow cells; the other 22 were contemporaneous control patients. RESULTS: With a mean followup of 32 +/- 26 months (range, 1-86 months), 12 recipients (3 intestine only, 9 composite grafts) are alive with good nutrition beyond the 5-year milestone. Forty-seven (48%) of the total group survive bearing grafts that provide full (91%) or partial (9%) nutrition. Actuarial patient survival at 1 and 5 years (72% and 48%, respectively) was similar with isolated intestinal and composite graft recipients, but the loss rate of grafts from rejection was highest with intestine alone. The best results were in patients between 2 and 18 years of age (68% at 5 years). Adjunct bone marrow did not significantly affect the incidence of graft rejection, B-cell lymphoma, or the rate or severity of graft-versus-host disease. CONCLUSIONS: These results demonstrate that longterm rehabilitation similar to that with the other kinds of organ allografts is achievable with all three kinds of intestinal transplant procedures, that the morbidity and mortality is still too high for their widespread application, and that the liver is significantly but marginally protective of concomitantly engrafted intestine. Although none of the endpoints were markedly altered by donor leukocyte augmentation (and chimerism) with bone marrow, establishment of the safety of this adjunct procedure opens the way to further immune modulation strategies that can be added to the augmentation protocol.
Asunto(s)
Inmunosupresores/uso terapéutico , Intestinos/trasplante , Análisis Actuarial , Adyuvantes Inmunológicos/administración & dosificación , Adyuvantes Inmunológicos/uso terapéutico , Adolescente , Adulto , Factores de Edad , Trasplante de Médula Ósea , Niño , Preescolar , Estudios de Factibilidad , Femenino , Estudios de Seguimiento , Rechazo de Injerto/etiología , Supervivencia de Injerto , Enfermedad Injerto contra Huésped/etiología , Humanos , Inmunosupresores/administración & dosificación , Inmunosupresores/efectos adversos , Incidencia , Lactante , Transfusión de Leucocitos , Trasplante de Hígado , Linfoma de Células B/etiología , Masculino , Persona de Mediana Edad , Fenómenos Fisiológicos de la Nutrición , Factores de Riesgo , Seguridad , Tasa de Supervivencia , Tacrolimus/administración & dosificación , Tacrolimus/efectos adversos , Tacrolimus/uso terapéutico , Quimera por Trasplante , Inmunología del Trasplante , Trasplante Homólogo , Resultado del TratamientoRESUMEN
BACKGROUND: The aim of this study was to report the influence of hepatitis C virus (HCV) genotypes and HLA matches on the outcome of liver transplantation, hepatitis recurrence, and progression to cirrhosis after transplantation. METHODS: HCV genotypes were determined from pretransplantation sera and/or liver explant tissues from 202 patients with HCV-related end-stage liver disease. One hundred fifty patients with known infecting genotype for whom posttransplantation biopsy specimens were available or who had normal results of liver injury tests constituted the group analyzed. Patients were followed up for up to 4.5 years. Hepatitis activity index scores at the time of disease recurrence were used to assess disease activity. Cirrhosis was diagnosed by using histological evidence. The number of HLA matches with respect to A, B, DR, and DQ loci was determined. RESULTS: The rates of hepatitis recurrence were 25% and 75% at 1 year and 4 years, respectively; Kaplan-Meier survival analysis did not reveal significant differences between the infecting genotypes with respect to overall rates of survival or recurrence of hepatitis. At hepatitis recurrence, hepatitis activity index scores did not differ between the genotype groups. The distribution of infecting genotypes among the 7 patients who developed cirrhosis is reflective of pretransplantation distribution. Neither HLA site-specific nor total matches affected the rates of survival or disease recurrence. CONCLUSIONS: The infecting HCV genotype had no influence on the incidence or severity of recurrent hepatitis, rate of survival, or development of cirrhosis. HLA matching does not influence transplantation outcome for HCV-related disease.
Asunto(s)
Hepacivirus/genética , Trasplante de Hígado/mortalidad , Adulto , Anciano , Femenino , Genotipo , Hepacivirus/clasificación , Prueba de Histocompatibilidad , Humanos , Cirrosis Hepática/diagnóstico , Masculino , Persona de Mediana Edad , Recurrencia , Tasa de Supervivencia , Resultado del TratamientoAsunto(s)
Intestinos/trasplante , Trasplante de Hígado/estadística & datos numéricos , Trasplante Homólogo/estadística & datos numéricos , Adolescente , Adulto , Niño , Preescolar , Femenino , Supervivencia de Injerto , Hospitales Universitarios/estadística & datos numéricos , Humanos , Terapia de Inmunosupresión/métodos , Inmunosupresores/efectos adversos , Inmunosupresores/uso terapéutico , Trasplante de Hígado/mortalidad , Trasplante de Hígado/fisiología , Masculino , Persona de Mediana Edad , Pennsylvania , Embarazo , Estudios Retrospectivos , Tasa de Supervivencia , Tacrolimus/efectos adversos , Trasplante Homólogo/mortalidad , Trasplante Homólogo/fisiologíaRESUMEN
The applicability of liver transplantation for ALD remains limited because of ethical arguments and also because of the perception of poor outcome after transplantation. Patients with alcoholic cirrhosis are known to do as well as patients with nonalcoholic liver disease after receiving liver allografts; however, the outcome in patients with severe acute alcoholic hepatitis in this setting is unclear. We studied 9 liver transplant recipients in whom severe acute alcoholic hepatitis was retrospectively diagnosed; 8 had underlying cirrhosis, and 1 had advanced fibrosis. All had Maddrey's discriminant function > 32, and most had hepatic encephalopathy and hepatorenal syndrome. History regarding abstinence was unreliable in some patients. Episodes of acute cellular rejection responded quickly to therapy, and despite recidivism in some patients, long-term survival was comparable to that of patients receiving transplants with alcoholic cirrhosis alone and those with a milder degree of alcoholic hepatitis and cirrhosis. This study suggests that severe acute alcoholic hepatitis may not be an appropriate contraindication for liver transplantation.
Asunto(s)
Hepatitis Alcohólica/cirugía , Trasplante de Hígado , Calidad de Vida , Adulto , Alcoholismo/epidemiología , Femenino , Supervivencia de Injerto , Hepatitis Alcohólica/mortalidad , Humanos , Trasplante de Hígado/mortalidad , Masculino , Recurrencia , Estudios Retrospectivos , Tasa de Supervivencia , Resultado del TratamientoRESUMEN
Epstein-Barr-virus-associated posttransplant lymphoproliferative disease ranges from transient lymphadenitis to aggressive lymphoma. This study characterizes an in vitro model to study the pathogenesis of this disease with a cell culture system. Five B-cell lines derived from posttransplant lymphoproliferative disease tissue were characterized with regard to immunophenotype, karyotype, molecular genetics, cytokine production, and growth regulation. All cell lines expressed CD19, CD21, CD22, CD43, and CD77, but not CD10 antigens. Immunoglobulin light chain restriction was seen in four of five cell lines, and cytogenetic abnormalities were demonstrable in three of the five. Cells proliferating in culture contained multiple Epstein-Barr virus episomes and showed lytic viral replication. All cell lines produced tumor necrosis factor-beta and interleukin-10 without evidence of autocrine growth regulatory loops involving these cytokines. No evidence of IL-1 alpha, IL-2, IL-4, IL-5 or IL-6 production was found by reverse transcriptase polymerase chain reaction. Adding 500 U IFN-alpha/ml to the culture medium resulted in 30% inhibition of [3H]thymidine incorporation.
Asunto(s)
Linfocitos B/metabolismo , Citocinas/biosíntesis , Herpesvirus Humano 4 , Interferón-alfa/farmacología , Trastornos Linfoproliferativos/virología , Trasplante de Órganos/efectos adversos , Adulto , Linfocitos B/inmunología , Línea Celular , Niño , Femenino , Reordenamiento Génico , Infecciones por Herpesviridae/patología , Herpesvirus Humano 4/crecimiento & desarrollo , Humanos , Inmunofenotipificación , Interleucina-10/biosíntesis , Interleucinas/biosíntesis , Cariotipificación , Trastornos Linfoproliferativos/genética , Trastornos Linfoproliferativos/inmunología , Linfotoxina-alfa/biosíntesis , Masculino , Infecciones Tumorales por Virus/patologíaRESUMEN
It has been postulated that the resident "passenger" leukocytes of hematolymphoid origin that migrate from whole organ grafts and subsequently establish systemic chimerism are essential for graft acceptance and the induction of donor-specific nonreactivity. This phenomenon was augmented by infusing 3 x 10(8) unmodified donor bone-marrow cells into 40 patients at the time of organ transplantation. Fifteen of the first 18 analyzable patients had sequential immunological evaluation over postoperative intervals of 5 to 17 months, (which included 7 kidney (two with islets), 7 liver (one with islets), and one heart recipient). The evolution of changes was compared with that in 16 kidney and liver nonmarrow controls followed for 4 to 5 months. The generic immune reactivity of peripheral blood mononuclear cells (PBMC) was determined by their proliferative responses to mitogens (PHA, ConA). Alloreactivity was measured by the recipient mixed lymphocyte reaction (MLR) to donor and HLA-mismatched third-party panel cells. Based on all 3 tests, the recipients were classified as donor-specific hyporeactive, intermediate, and responsive; patients who were globally suppressed made up a fourth category. Eight (53%) of the 15 marrow-treated recipients exhibited progressive modulation of donor-specific reactivity (3 hyporeactive and 5 intermediate) while 7 remained antidonor-responsive. In the nonmarrow controls, 2 (12.5%) of the 16 patients showed donor-specific hyporeactivity, 10 (62.5%) were reactive, and 4 (25%) studied during a CMV infection had global suppression of responsiveness to all stimuli.
Asunto(s)
Trasplante de Médula Ósea/inmunología , Supervivencia de Injerto/inmunología , Isoanticuerpos/inmunología , Leucocitos Mononucleares/inmunología , Trasplante de Órganos , Adulto , División Celular/efectos de los fármacos , Células Cultivadas , Citotoxicidad Inmunológica , Estudios de Seguimiento , Humanos , Terapia de Inmunosupresión , Isoanticuerpos/biosíntesis , Leucocitos Mononucleares/patología , Linfocitos/inmunología , Linfocitos/patologíaRESUMEN
Tacrolimus is a more potent and satisfactory immunosuppressant than CyA for combination therapy with prednisone. In randomized trials comparing the 2 drugs, the ability of tacrolimus to rescue intractably rejecting grafts on the competing CyA arm allowed equalization of patient and graft survival on both arms when the intent-to-treat analytic methodology was applied. The ability of tacrolimus to systematically rescue the treatment failures of CyA suggested, as a matter of common sense, that it is the preferred baseline drug for hepatic transplantation. This conclusion was supported by analysis of secondary end points, including the ability to prevent rejection. Hepatic-intestinal, multivisceral and isolated intestinal transplantation became feasible on a practical basis only after the advent of tacrolimus. Nevertheless, better management strategies must be devised before intestinal transplantation, alone or with other abdominal viscera, will meet its potential. One such strategy is based on the discovery of the presence of previously unsuspected, low-level donor leukocyte chimerism in long-surviving allograft recipients. We believe that this chimerism is the essential explanation for the feasibility of organ transplantation and a link to the acquired neonatal tolerance demonstrated by Billingham, Brent and Medawar (32). The hematolymphopoietic chimerism in organ recipients explains why weaning to a drug-free state in selected long-term survivors is frequently feasible and particularly if the allograft is a liver. Weaning should never be attempted without a stepwise protocol and careful monitoring of graft function. Recognition of the natural chimerism that develops after whole organ transplantation has led to efforts to augment it with perioperative donor BM infusion. This procedure has been shown to be free of significant complications (including GVHD) in all kinds of whole organ recipients, including those given intestine. The prospects of clinical xenotransplantation must be evaluated in the same context of chimerism as that delineated for allotransplantation with the discovery of spontaneous chimerism. Before addressing chimerism-related questions in xenotransplantation, the additional barrier of the complement activation syndromes that cause hyperacute rejection will have to be surmounted. Although measures to effectively transplant xenografts have so far eluded us, the availability of the more potent drug, tacrolimus, and recognition of the seminal basis of allograft (or xenograft) acceptance via chimerism has inserted an element of reality into the largely wishful thinking that has been evident in discussions about the future of xenotransplantation.
Asunto(s)
Trasplante de Hígado , Adolescente , Adulto , Trasplante de Médula Ósea , Protocolos Clínicos , Estudios Cruzados , Ciclosporina/uso terapéutico , Femenino , Rechazo de Injerto/prevención & control , Humanos , Inmunosupresores/uso terapéutico , Intestinos/trasplante , Transfusión de Leucocitos , Trasplante de Hígado/efectos adversos , Trasplante de Hígado/métodos , Trasplante de Hígado/mortalidad , Masculino , Persona de Mediana Edad , Estudios Multicéntricos como Asunto , Pennsylvania , Prednisona/uso terapéutico , Ensayos Clínicos Controlados Aleatorios como Asunto , Reoperación , Tasa de Supervivencia , Tacrolimus/uso terapéutico , Donantes de TejidosRESUMEN
Interleukin-10 (IL-10) is a cytokine known to regulate growth and differentiation in activated human B cells. We studied IL-10 production in a B-cell line derived from Epstein-Barr virus associated post-transplant lymphoproliferative disease (PTLD). Reverse transcriptase polymerase chain reaction (RT-PCR) demonstrated IL-10 mRNA within the cells. Transcripts of the virally encoded homologue BCRF-1 were not detected. ELISA assays demonstrated translation of IL-10 message into the corresponding cytokine, and its subsequent secretion into the culture medium. The rate of 3H-thymidine incorporation by the PTLD cells was not affected by immunologic neutralization of the secreted cytokine, or, by addition of exogenous recombinant IL-10 to the culture medium. Thus, IL-10 does not have an autocrine growth regulatory role in this PTLD line.
Asunto(s)
Linfocitos B/metabolismo , Interleucina-10/biosíntesis , Trastornos Linfoproliferativos/metabolismo , Trastornos Linfoproliferativos/patología , Secuencia de Bases , División Celular/fisiología , Línea Celular , Cartilla de ADN , Infecciones por Herpesviridae , Herpesvirus Humano 4 , Humanos , Trasplante de Hígado/efectos adversos , Trastornos Linfoproliferativos/virología , Datos de Secuencia Molecular , Reacción en Cadena de la Polimerasa , Transcripción Genética , Infecciones Tumorales por VirusRESUMEN
We studied seven patients aged 14 to 40 years who received living-related kidney transplants and had allograft survivals of 26 to 29 years. The blood urea and creatinine were either within normal limits or marginally elevated. Histopathologic examination showed only mild mesangial expansion, interstitial fibrosis, and arteriosclerosis. Immunoperoxidase staining with anti-HLA antibodies or in situ hybridization with a Y chromosome probe showed persistence of donor tubular epithelium and vascular endothelium within the graft. Recipient-derived glomerular cells were seen in one case, and interstitial lymphocytic infiltrates were seen in all cases. A review of the clinicopathologic data available for these cases indicated that both central and peripheral immunologic mechanisms contributed to the maintenance of prolonged graft survival. This extended survival was independent of six antigen matching, down-regulation of donor HLA antigen expression, and ingrowth of host epithelium/endothelium into the allograft.
Asunto(s)
Supervivencia de Injerto , Antígenos HLA/análisis , Glomérulos Renales/patología , Trasplante de Riñón , Cromosoma Y , Adolescente , Adulto , Femenino , Supervivencia de Injerto/inmunología , Supervivencia de Injerto/fisiología , Humanos , Hibridación in Situ , Trasplante de Riñón/inmunología , Trasplante de Riñón/patología , Trasplante de Riñón/fisiología , MasculinoRESUMEN
Epstein-Barr virus encoded RNA's (EBER) are small RNA species found in cells latently infected by the virus. The physiological function of these molecules is currently a matter of speculation. Nonetheless, their presence in extremely high copy number has made it possible to reliably detect the Epstein-Barr virus by in-situ hybridization, in human tissues routinely fixed with formalin and embedded in paraffin. Such studies have enhanced our understanding of a number of hematologic malignancies, particularly Hodgkin's disease, angiocentric immunoproliferative lesions and angio-immunoblastic lymphadenopathy. In addition, sequential EBER in-situ hybridization studies on lymphoid tissues should enable oncologists to monitor the development of lymphoproliferative disorders occurring in the setting of organ transplantation, AIDS and hereditary immunodeficiencies.
Asunto(s)
Enfermedades Hematológicas/genética , Enfermedades Hematológicas/microbiología , Infecciones por Herpesviridae/genética , Infecciones por Herpesviridae/microbiología , Herpesvirus Humano 4/genética , Neoplasias/genética , Neoplasias/microbiología , Proteínas de Unión al ARN/genética , Proteínas Ribosómicas , Infecciones Tumorales por Virus/genética , Infecciones Tumorales por Virus/microbiología , HumanosAsunto(s)
Trasplante de Hígado/estadística & datos numéricos , Adolescente , Adulto , Anciano , Animales , Enfermedades Autoinmunes/epidemiología , Enfermedades Autoinmunes/cirugía , Trasplante de Médula Ósea , Niño , Preescolar , Cricetinae , Demografía , Femenino , Predicción , Refuerzo Inmunológico de Injertos , Supervivencia de Injerto , Enfermedad Injerto contra Huésped/prevención & control , Hospitales Universitarios/estadística & datos numéricos , Humanos , Terapia de Inmunosupresión/métodos , Lactante , Tablas de Vida , Hepatopatías/epidemiología , Hepatopatías/cirugía , Trasplante de Hígado/mortalidad , Trasplante de Hígado/rehabilitación , Trasplante de Hígado/tendencias , Masculino , Persona de Mediana Edad , Pennsylvania/epidemiología , Ratas , Reoperación/estadística & datos numéricos , Estudios Retrospectivos , Factores de Riesgo , Análisis de Supervivencia , Tacrolimus/uso terapéutico , Trasplante Heterólogo , Resultado del TratamientoRESUMEN
A topic of current interest in islet transplantation is the selection of an optimal site for long-term graft survival since the intrahepatic site may be characterized by long-term failure. Additionally, the use of immunosuppressive agents such as prednisone may adversely affect long-term graft function. In this study, we examined the long-term outcome of intrahepatic canine islet autografts and compared this with results obtained in animals treated with a short-term course of steroids or steroids plus insulin. Islets were isolated using the automated method and were purified on discontinuous Euro-Collins Ficoll gradients (densities: 1.108, 1.096, 1.037). Prednisone-treated dogs were hyperglycemic during treatment but returned to normoglycemia after steroid withdrawal. Control and insulin-treated animals were normoglycemic following autotransplant, with no difference in plasma glucose levels between controls and the insulin-treated animals. All control dogs became diabetic at 11, 14, 17, and 19 months following islet autograft. Prednisone-treated dogs had more rapid onset of diabetes at 7, 11, and 12 months following ITx. Prednisone-treated dogs given insulin became hyperglycemic at 10, 14, 18, and 19 months post ITx. Graft failure was preceded by a decline in IVGTT Kg values and diminished insulin secretion. At the time of graft failure islets showed no lymphocytic infiltration and islets stained positive for glucagon but few insulin-containing cells were seen. Thus, even when an initially adequate B cell mass was transplanted, the intrahepatic site was characterized by long-term canine autograft failure. A short course of prednisone accelerated the time to graft failure and insulin treatment reversed this acceleration.